Abstract 766P
Background
Prolongation of overall treatment time (OTT) in carcinoma cervix is well known to adversely affect local control and survival. The OTT would be unduly prolonged if brachytherapy (BT) was started only after completion of external beam radiation (EBRT) as multiple insertions are required for high-dose-rate BT. This study was carried out to compare treatment outcomes of shortening the OTT by interdigitated BT as opposed to conventional sequential BT in terms of late toxicities, disease free survival (DFS) and overall survival (OS).
Methods
The study included 70 patients of cancer cervix who met the inclusion criteria. Patients were randomized into study and control arms. All the patients received EBRT (45Gy/20 fractions over 4 weeks) with concurrent Cisplatin and 3 fractions of BT (7 Gy/fraction). Patients in the control arm received weekly BT after one week following EBRT to complete the entire treatment in 7 weeks. In the study arm, BT was interdigitated with EBRT after 15 fractions. Subsequent BT fractions were given on days 27 and 34 to complete the treatment in 5 weeks. The two groups were compared in terms of late toxicities, DFS and OS at a follow up of two years.
Results
A total of 63 patients completed the planned treatment. The OTT and mean biologically equivalent dose (BED10Gy) after reduction for accelerated repopulation was significantly better in the study arm (p=0.001). At two years of follow up, 80% of patients in the study arm and 72.72% in the control arm had no local or distant failure. Also, death occurred in 13.33% patients and 18.18% patients in the study and control arm, respectively. No statistically significant difference was reached in terms of OS and DFS despite a trend towards better DFS in the interdigitated BT arm. The incidence of late lower gastro-intestinal toxicities was found to be higher in the study arm but this difference was not significant.
Conclusions
Interdigitated BT with chemoradiation appears to be an acceptable option for shortening OTT with similar survival outcomes and acceptable toxicities in comparison to sequential brachytherapy. Owing to a shorter OTT, this approach is radiobiologically superior with a more efficient utilization of machines at centers with heavy patient load.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11